1. Home
  2. JRVR vs PROF Comparison

JRVR vs PROF Comparison

Compare JRVR & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JRVR

James River Group Holdings Ltd.

HOLD

Current Price

$4.13

Market Cap

288.2M

Sector

Finance

ML Signal

HOLD

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

N/A

Current Price

$6.91

Market Cap

243.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JRVR
PROF
Founded
2002
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.2M
243.2M
IPO Year
2014
2017

Fundamental Metrics

Financial Performance
Metric
JRVR
PROF
Price
$4.13
$6.91
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$7.33
$12.00
AVG Volume (30 Days)
538.7K
69.1K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
0.64%
N/A
EPS Growth
125.82
25.89
EPS
N/A
0.19
Revenue
$687,614,000.00
$16,098,000.00
Revenue This Year
N/A
$92.40
Revenue Next Year
$1.61
$64.10
P/E Ratio
N/A
$36.39
Revenue Growth
N/A
50.73
52 Week Low
$3.76
$3.92
52 Week High
$7.20
$8.95

Technical Indicators

Market Signals
Indicator
JRVR
PROF
Relative Strength Index (RSI) 27.71 51.69
Support Level $3.76 $5.81
Resistance Level $5.61 $7.07
Average True Range (ATR) 0.29 0.41
MACD -0.03 -0.04
Stochastic Oscillator 14.40 26.72

Price Performance

Historical Comparison
JRVR
PROF

About JRVR James River Group Holdings Ltd.

James River Group Holdings Inc is a holding company that owns and operates a group of specialty insurance companies focused on underwriting small and middle market casualty risks within the U.S. excess and surplus (E&S) lines market. The Company operates in two specialty property-casualty insurance segments: Excess and Surplus Lines and Specialty Admitted Insurance.

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

Share on Social Networks: